Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
about
Personalized management of essential thrombocythemia-application of recent evidence to clinical practicePolycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementRefractory anemia with ring sideroblasts and RARS with thrombocytosisAdvanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk?Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burdenPharmacological management of essential thrombocythemia.Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome.Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating studyPatterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution.Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaClinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.Splanchnic vein thrombosis in myeloproliferative neoplasms.Are MPNs vascular diseases?Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)Therapeutic apheresis for patients with cancer.A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.Advances and challenges in the management of essential thrombocythemia.Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.
P2860
Q24632447-6C533F42-0DA9-4236-9E21-E97873F5955DQ26851894-C2BE9422-281C-4018-B63A-220F0ADE31B1Q28083238-16936345-E8B4-43E2-8FAC-3FB7120E9C71Q30518002-5F3F3A2D-0E0E-47E1-BC4E-713CE383097CQ33359341-9727EF3F-E857-4AB1-9CE5-7309C1828BF3Q33434734-C3C5FD3D-CBBD-4AB6-8948-CE52D9B6148BQ34037065-9EDD458C-444B-4636-BB93-4C397CD39D82Q34189794-5043206F-E89A-4552-9714-E25E8D8C0E3DQ34344384-6E4DAE9C-9386-46DF-B1BB-ADE698577514Q34370771-D830C89C-9224-459B-8F93-8D06BBA44E84Q35188877-D8994E47-C256-44EA-8E65-084C815FD21FQ35598864-F14DD305-0C89-47CC-A69E-7CFEFD21B151Q35636700-6C194768-2AB1-47C6-8DBA-1E3D013198A0Q36157668-1D792CAA-5FCD-4540-BED8-6016732FF15FQ36502712-49001FFD-CA65-4712-901F-A1CE6E78948DQ36666769-45A6B906-1136-4329-B51E-DF50191E06DEQ36874807-99C42076-518C-4C2F-8DB6-8360FC3217F5Q37157892-A9DC995A-2F4E-4FEB-AE61-EA13AABB84CFQ37417438-B2C2288E-5656-498B-B988-37DA3924F765Q37623539-628A1954-2306-4B97-B021-D7643D10C855Q37638779-D163C3E5-43F0-4A7C-8DBB-D072AA9460A3Q37672905-203DB6A9-4A26-4A9F-BAD2-645F8A45596EQ37679175-B7C71FEB-50CB-4DC0-B933-AD743E90013CQ37934479-489926E3-EE69-4F2D-9FBC-47AC4F6F3496Q37983791-7C455859-1FFF-4482-BB3F-21DB07009626Q38087202-4932663F-34B5-400B-8513-1BDECBA5A578Q38100371-D3066575-2AE0-433D-9C27-03039502E031Q38121635-F374E08F-700F-4FD1-93E5-D7EF24138492Q38137750-F0E91B28-10BB-478E-B637-5C7D4B23BEFFQ38187675-FCE14F6E-439C-4578-B1DB-7C98C120109FQ38210664-80D7E26F-31B3-441E-B178-55AF23C295DFQ38242725-DC343237-917F-4E5F-B5C8-46A265A1D867Q38287610-A58B259F-DE7E-4E09-A98C-F2F2352A2EE0Q38300431-5E40D897-C955-417F-B66E-97CB05D1CED1Q38542093-36E434E9-61D5-44F3-A780-C504BEC090D2Q38742500-0A8D016E-CEB4-45A5-A0E0-9DB7F6D8E218Q38917400-6CB39B2E-8C02-4168-8DDE-772AEFA8DCC3Q39041471-168CC783-AC55-43FB-8D4F-A71E7389089DQ39124885-420AA0CA-D474-4C23-8D47-C7077D4035D1Q39306368-534EBA25-4C48-4207-B01A-A943A7E7B518
P2860
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk factors for arterial and ...... ational study of 891 patients.
@en
Risk factors for arterial and ...... ational study of 891 patients.
@nl
type
label
Risk factors for arterial and ...... ational study of 891 patients.
@en
Risk factors for arterial and ...... ational study of 891 patients.
@nl
prefLabel
Risk factors for arterial and ...... ational study of 891 patients.
@en
Risk factors for arterial and ...... ational study of 891 patients.
@nl
P2093
P921
P1433
P1476
Risk factors for arterial and ...... ational study of 891 patients.
@en
P2093
Alessandra Carobbio
Alessandro M Vannucchi
Elisa Rumi
Elisabetta Antonioli
Francesco Passamonti
Francesco Rodeghiero
Guido Finazzi
Heinz Gisslinger
Irene Bertozzi
Juergen Thiele
P304
P356
10.1182/BLOOD-2011-02-339002
P407
P577
2011-04-13T00:00:00Z